The Negative Impact of Biological Variation in the Effect and Clearance of Warfarin on Methods for Prediction of Dose Requirements

Summary

Within-individual variation over time in the clearance (Cl) and effect (PT%) of warfarin, was measured in 25 inpatients (group I) studied after standard single or individualized split loading doses and 1-3 times (n = 16) 8-16 weeks later during maintenance. Mean Cl (2.5 α 0.9 ml/min) was similar in both phases but significant changes occurred in 6/16 patients, exceeding those expected from within-individual variation alone (defined by its 95% tolerance limits -24% to +62%). Initial PT% (21 α 5) was unaffected by dosing schedule, total or free plasma warfarin, varying between patients by only 18-24%. Mean initial and maintenance dose-PT% ratios (8.2 mg/d: 21% and 4.1 mg/d: 40%) were similar but significant changes in sensitivity to warfarin occurred in 4/16 patients. In group I and 64 other outpatients on maintenance therapy, between-individual variability was 36-52% for Cl and 49-56% for effect. PT% correlated best (r = 0.56) with free and total plasma warfarin but poorly with dose (r = 0.29), with only 30% of PT% variance explained at best, due to high between patient variability.

Warfarin dose prediction whether based on extrapolation from initial effects to the maintenance phase, or on iterative methods not allowing for between- or within-patient variation in warfarin clearance or effect which may occur independently over time, have not improved on empirical therapy. This, due to the elements of biological variability as well as the intricacy of the warfarin - prothrombin complex interaction not captured by any kinetic-dynamic model used for prediction to date.

Keywords

Warfarin - Anticoagulation - Dose prediction - Clearance - Variability

• References

• 1 Routledge PA, Davies DM, Bell SM, Cavanagh JS, Rawlins MD. Predicting patients warfarin requirements. Lancet 1977; 2: 854-855
• 2 Williams BD, Karl RC. A simple technic for predicting daily maintenance dose of warfarin. Amer J Surg 1979; 137: 572-576
• 3 Sawyer WT. Predictability of warfarin dose requirements: theoretical considerations. J Pharm Sci 1979; 68: 432-434
• 4 Miller DR, Brown MA. Predicting warfarin maintenance dosage based on initial response. Am J Hosp Pharm 1979; 36: 1351-1355
• 5 Sharma NK, Routledge PA, Rawlins MD, Davies DM. Predicting the dose of warfarin for therapeutic anticoagulation. Thromb Haemostas 1982; 47: 230-231
• 6 Dobrzanski S. Predicting warfarin dosage. J Clin Hosp Pharm 1983; 8: 247-250
• 7 Wilson R, James AH. Computer assisted management of warfarin treatment. Br Med J 1984; 289: 422-424
• 8 Theophanous TG, Barile RG. Multiple dose kinetics of oral anticoagulants: Methods of analysis and optimized dosing. J Pharm Sci 1973; 62: 261-266
• 9 Powers WF, Abbrecht PH, Covell DG. Systems and microcomputer approach to anticoagulant therapy IEEE Trans Biomed Engin. 1980; 27: 520-824
• 10 Abbrecht PH, O’Leary TJ, Behrendt DM. Evaluation of a computer assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model. Clin Pharm Ther 1982; 32: 129-136
• 11 Svec JM, Coleman RW, Mungall DR, Ludden TM. Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to warfarin therapy: a preliminary evaluation. Therapeutic Drug Monitoring 1985; 7: 174-180
• 12 Thomson JM. Laboratory control of anticoagulant therapy. In: Blood coagulation and hemostasis. 319-320 Publ. Churchill and Livingstone; London: 1980
• 13 Forman WB, Shales J. Comparison of high performance liquid chromatography and a spectrophotometric technique for determining plasma warfarin. J Chromat 1978; 146: 522-526
• 14 Gibaldi M, Perrier D. One compartment model. In: Pharmacokinetics 2nd edition 33-40 Publ. Marcel Dekker Inc; New York: 1982
• 15 Nichols AI, Peck CC. LSNLR, general weighted least squares nonlinear regression program. Technical report No. 5.0. Division of Clinical Pharmacology, Department of Pharmacology and Medicine, Uniformed Services University of the Health. Sciences, Bethesda Md, May 1981
• 16 Rowland M, Tozer TN. Dosage regimens. In: Clinical pharmacokinetics. Concepts and applications. 113-117 Publ. Lea and Febiger; Philadelphia: 1980
• 17 Dixon WJ, Massey FJ. Introduction to statistical analysis. 3rd ed 142 Publ. McGraw-Hill Co.; New York: 1969
• 18 Holford NH G, Sheiner LB. Understanding the dose effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinetics 1981; 6: 429-453
• 19 Routledge PA, Chapman PH, Davies DM, Rawlins MD. Pharmacokinetics and pharmacodynamics of warfarin at steady state. Br J Clin Pharmac 1979; 8: 243-247
• 20 Benet LZ, Sheiner LB. Design and optimization of dosage regimens; pharmacokinetic data. Appendix II. In: The pharmacologic basis of therapeutics. 7th edition Goodman Gilman A, Goodman LS, Rail TW, Murad F. (Eds.) 1663-1713 Publ Macmillan Publishing Co; New York: 1985
• 21 Mungall DR, Ludden TM, Marshall J, Hawkins DW, Talbert RL, Crawford MH. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokin Biopharmac 1985; 13: 213-227
• 22 O’Reilly RA. Anticoagulant, antithrombotic and thrombolytic drugs. In: The pharmacologic basis of therapeutics. 7th edition Goodman Gilman A, Goodman LS, Rail TW, Murad F. (Eds.) 1345 Publ. Macmillan Publishing Co. New York: 1985
• 23 Mungall D, Ludden TM, Marshall J, Crawford M, Hawkins D. Relationships between steady state warfarin concentrations and anticoagulant effect. Clin Pharmacokin 1984; 9 (Supp. I) 99-100
• 24 Yacobi A, Levy G. Protein binding of warfarin enantiomers in serum of humans and rats. J Pharmacokin Biopharmac 1977; 5: 123-131
• 25 Bachman K, Shapiro R. Protein binding of coumarin anticoagulants in disease states. Clin Pharmacokin 1977; 2: 110-126
• 26 Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokin Biopharmaceutics 1981; 9: 503-512
• 27 Gordon BM, Wisere TH, Davis JD. Warfarin maintenance dose prediction based upon initial anticoagulant response. Clin Pharm 1984; 3: 297-299
• 28 Lee C, Coleman RW, Mungall DR. Influence of warfarin plasma concentrations on pharmacodynamic predictions. Clin Pharm Ther 1986; 39: 206
• 29 Mungall D, Lopez D, Warfcalc AschR. A computer program for managing warfarin therapy. Publisher-Biotrack Inc; Sunnyvale, California: 1984
• 30 D’Angelo SV, Comp PC, Esmon CT, D’Angelo A. Relationship between protein C and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986; 77: 416-425
• 31 Hirsh J, Deykin D, Poller L. Therapeutic range for oral anticoagulant therapy. Chest 1986; 89 (No. 2, Supp.) 11S-5S